SEARCH

SEARCH BY CITATION

References

  • 1
    Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal cell carcinoma: 1983-1993. Semin Oncol. 1995; 22: 42-60.
  • 2
    Motzer RJ, Vogelzang NJ. Chemotherapy for renal cell carcinoma. In: RaghavenD, ScherHI, LeibelSA, et al. eds. Principles and Practice of Genitourinary Oncology. Philadelphia, PA: Lippincott-Raven; 1997: 885-896.
  • 3
    Pickle LW, Hao Y, Jemal A, et al. A new method of estimating United States and state-level cancer incidence counts for the current calendar year. CA Cancer J Clin. 2007; 57: 30-42.
  • 4
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 43-66.
  • 5
    Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-124.
  • 6
    Figlin RA, Hutson TE, Tomczak P, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) [abstract]. Proc J Clin Oncol. 2008; 26( suppl): 256s. Abstract 5024.
  • 7
    Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced renal cell carcinoma. N Engl J Med. 2007; 356: 125-134.
  • 8
    Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa or both for advanced renal cell carcinoma. N Engl J Med. 2007; 356: 2271-2281.
  • 9
    Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370: 2103-2111.
  • 10
    Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon-alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008; 26: 5422-5428.
  • 11
    Motzer RJ, Escudier B, Oudard S, et al. Efficacy at everolimus in advanced renal cell carcinoma: a double blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372: 449-456.
  • 12
    Rixe O, Bukowski R, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007; 8: 975-984.
  • 13
    Rini BI, Wilding GT, Hudes G, et al. Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol. 2007; 25( 18 suppl): 5032.
  • 14
    Hutson TE, Davis ID, Machiels JP, et al. Biomarker analysis and final results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor [abstract]. Proc J Clin Oncol. 2008; 26( suppl): 261s. Abstract 5046.
  • 15
    Hutson TE, Davis ID, Machiels JP, et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): interim results of a phase II randomized discontinuation trial (RDT). J Clin Oncol. 2007; 25( 18 suppl): 5031.
  • 16
    Eder JP, Appleman L, Heath E, et al. A phase I study of a novel spectrum selective kinase inhibitor (SSKI), XL880, administered orally in patients (pts) with advanced solid tumors (STs). J Clin Oncol. 2006; 24( 18 suppl): 3041.
  • 17
    Eder JP, Heath E, Appleman L, et al. Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors. J Clin Oncol. 2007; 25( 18 suppl): 3526.
  • 18
    Ross RW, Stein M, Sarantopoulos J, et al. A phase II study of the c-Met RTK inhibitor XL880 in patients (pts) with papillary renal-cell carcinoma (PRC). J Clin Oncol. 2007; 25( 18 suppl): 15601.
  • 19
    Stephenson J, Schreeder M, Waples J, et al. Perifosine (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKI). J Clin Oncol. 2007; 25( 18 suppl): 15622.
  • 20
    Yu Y, Varughese J, Brown LF, et al. Increased Tie-2 expression, enhanced response to angiopoietin-1 and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Am J Pathol. 2001; 159: 2271-2280.
  • 21
    Gale N, Thurston G, Hackett S, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Cell. 2002; 3: 411-423.
  • 22
    Currie MJ, Gunningham SP, Turner K, et al. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. J Pathol. 2002; 198: 502-510.
  • 23
    AMG 386 Investigator Brochure.
  • 24
    Rosen LS, Hong D, Chap L, et al. First-in-human study of AMG 386, a selective angiopoietin1/2-neutralizing peptibody, in adult patients with advanced solid tumors. J Clin Oncol. 2007; 25( 18 suppl): 3522.
  • 25
    Dupont J, Rothenberg ML, Spriggs DR, et al. Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors. J Clin Oncol. 2005; 23( 16 suppl): 3029.
  • 26
    Yang JC, Beck KE, Blansfield JA, et al. Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010). J Clin Oncol. 2005; 23( 16 suppl): 2501.
  • 27
    Griffiths RW, Gilham DE, Dangoor A, et al. Expression of the 5T4 oncofetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer. 2005; 93: 670-677.
  • 28
    Harrop R, Macdermott C, Shablak A, et al. Vaccination of renal cell cancer patients with TroVax (modified vaccinia Ankara delivering the tumor antigen 5T4) plus IFNα: a phase II trial [abstract]. J Clin Oncol. 2008; 26: 145s. Abstract 3053.
  • 29
    Hernandez-McClain J, Amato RJ, Shingler WH, et al. Vaccination of renal cell cancer (RCC) patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax T) administered + low dose interleukin-2 (IL-2 ): a phase II trial [abstract]. J Clin Oncol. 2008; 26: 274s. Abstract 5101.